Immuneering (IMRX) Capital Expenditures (2020 - 2024)
Historic Capital Expenditures for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to $9356.0.
- Immuneering's Capital Expenditures fell 9452.6% to $9356.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $84875.0, marking a year-over-year decrease of 7523.68%. This contributed to the annual value of $84875.0 for FY2024, which is 7523.68% down from last year.
- Immuneering's Capital Expenditures amounted to $9356.0 in Q4 2024, which was down 9452.6% from $5268.0 recorded in Q3 2024.
- Immuneering's Capital Expenditures' 5-year high stood at $393134.0 during Q3 2022, with a 5-year trough of $5268.0 in Q3 2024.
- Over the past 5 years, Immuneering's median Capital Expenditures value was $35125.5 (recorded in 2024), while the average stood at $70808.4.
- Per our database at Business Quant, Immuneering's Capital Expenditures surged by 336495.68% in 2022 and then tumbled by 9452.6% in 2024.
- Immuneering's Capital Expenditures (Quarter) stood at $38058.0 in 2020, then plummeted by 65.7% to $13052.0 in 2021, then surged by 430.97% to $69302.0 in 2022, then skyrocketed by 146.63% to $170918.0 in 2023, then crashed by 94.53% to $9356.0 in 2024.
- Its Capital Expenditures was $9356.0 in Q4 2024, compared to $5268.0 in Q3 2024 and $32773.0 in Q2 2024.